The main effects and common side effects of Enasidenib

Enasidenib is a targeted therapy drug mainly used to treat patients with acute myeloid leukemia (AML), especially those carrying IDH2 gene mutations. As a targeted inhibitor, ensidipine restores normal cell differentiation and inhibits the disordered proliferation of cancer cells by inhibiting the activity of IDH2 mutant enzyme. It provides new treatment options for AML patients, especially those who are not suitable for traditional chemotherapy. Although its efficacy is remarkable, it is also accompanied by certain side effects during use.

The core mechanism of action of ensidipine is to restore normal cell differentiation by inhibiting IDH2 mutant enzyme activity. In normal cells, the IDH2 enzyme participates in the glycolysis process and helps generate energy, but in cancer cells, mutations in the IDH2 gene lead to the accumulation of 2-hydroxyglutarate (2-HG). The accumulation of 2-HG will inhibit the normal cell differentiation process and lead to the disordered proliferation of cancer cells. Ensidipine inhibits the growth of tumor cells by inhibiting metabolic abnormalities caused by IDH2 mutations, reducing the accumulation of 2-HG, and restoring normal cell functions.

Another important effect of ensidipine is its application in the treatment of acute myeloid leukemia (AML). AML is a malignant disease of the hematopoietic system, and IDH2 gene mutations have a high incidence in this disease. By targeting the activity of IDH2 mutant enzyme, ensidipine can effectively improve the patient's bone marrow function, restore normal blood cell production, and significantly improve the patient's remission rate and survival.

One of the advantages of ensidipine is that it is suitable for AML patients who are not suitable for traditional chemotherapy. Chemotherapy is often associated with severe side effects, especially in older patients and those with other medical conditions. Ensidipine, as an oral targeted drug, has fewer side effects and can significantly improve patients' clinical symptoms, making it an ideal choice for the treatment of AML.

Although ensidipine has shown significant efficacy in the treatmentAML, it is still associated with certain side effects. Understanding these side effects can help patients better manage their health during treatment.

1. Abnormal liver function: One of the common side effects of ensidipine is abnormal liver function. Some patients may experience elevated liver enzymes (such as ALT, AST, etc.) during treatment. Abnormalities in these liver function markers are usually mild or moderate, but may lead to severe liver injury in some patients. Patients need regular monitoring of liver function during treatment, especially in the early stages of treatment. If liver enzymes are elevated, your doctor may adjust the drug dose or suspend ensidipine use, depending on the situation.

2. Hypokalemia: Hypokalemia is also a common side effect of ensidipine. Hypokalemia may cause patients to experience symptoms such as fatigue, muscle weakness, and heart palpitations. Electrolyte levels in the blood need to be checked regularly, especially during treatment. If hypokalemia is more severe, your doctor may recommend potassium supplements or adjustments to your treatment plan.

3. Nausea and Vomiting: Ensidipine may cause nausea and vomiting in some patients. These symptoms are usually mild and may gradually improve with treatment. If symptoms persist or worsen, patients should communicate with their doctor promptly so that treatment can be adjusted or auxiliary medications can be used to relieve discomfort.

4. Leukopenia and anemia: Patients taking ensidipine may experience hematological side effects such as leukopenia and anemia. Patients may feel tired, weak, or susceptible to infections. Routine blood tests are critical to detecting these side effects promptly. For patients who develop leukopenia or anemia, doctors may adjust drug dosages or take necessary treatment measures.

Reference materials:https://www.idhifa.com/